Zelluna ASA's Recent Capital Increase Announcement
Zelluna ASA recently achieved an important milestone by completing the registration of its new share capital. This development is primarily a result of a resolution passed by the Company's Board of Directors, allowing for the issuance of 227,096 new shares. These new shares were issued to compensate for an option exercise fee.
Newly Registered Share Capital Details
The new share capital has been formally registered with the Norwegian Register of Business Enterprises. As it stands, Zelluna ASA's total registered share capital has reached NOK 20,454,162. This amount is divided into 20,454,162 shares, each carrying a nominal value of NOK 1. This step is vital for the Company's future growth and operational strategies.
Contact Information for Inquiries
For those seeking more information about this recent development, Hans Vassgård Eid, the CFO of Zelluna ASA, is available for inquiries. You can reach him via email at hans.eid@zelluna.com or call +47 482 48632.
About Zelluna ASA and its Mission
The foundational mission of Zelluna ASA is to provide transformative cancer treatments with the potential to cure advanced solid tumors efficiently and safely on a global scale. The Company stands out by merging key elements of the immune system with its innovative “off the shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies, known as TCR-NK therapies.
The TCR-NK Platform
This pioneering platform features a remarkable mechanism of action, capable of detecting a wide array of cancers. It has been designed specifically to address the diverse nature of tumors encountered in clinical settings. By providing these treatments “off the shelf,” Zelluna aims to eliminate the scalability challenges faced by traditional cell therapies.
Leading the Fight Against Cancer
Zelluna ASA's lead program is the world's first MAGE-A4 targeting “off the shelf” TCR-NK therapy. This groundbreaking treatment is aimed at providing a new option for patients suffering from various solid cancers. Following this program, a pipeline of additional innovative products is in development, promising further advancements in the field of cancer therapy.
Expert Management Team
The Company is guided by a team of experienced biotech entrepreneurs, all of whom possess extensive expertise in the discovery and clinical development of TCR and cell-based therapies. Their combined knowledge and experience are integral in bringing innovative therapies to market, including those that are currently available to patients.
Frequently Asked Questions
What is Zelluna ASA's recent capital increase about?
Zelluna ASA has issued 227,096 new shares to cover an option exercise fee, increasing its registered share capital to NOK 20,454,162.
How can I contact Zelluna ASA for more information?
You can reach Hans Vassgård Eid, CFO of Zelluna ASA at hans.eid@zelluna.com or call +47 482 48632.
What is the main goal of Zelluna ASA?
Zelluna ASA aims to develop and provide transformative cancer treatments to patients worldwide, using innovative TCR-NK cell therapies.
What is TCR-NK therapy?
TCR-NK therapy is an innovative cancer treatment approach that combines T cell receptors with natural killer cells to enhance the immune system's ability to attack tumors.
What is the significance of the new share issue?
The new share issue is a crucial step for Zelluna ASA as it provides the necessary capital to support and expand their cancer treatment initiatives.
